 |
NYC Tech
Events Weekly
Newsletter! |
|
|
|
|
| |
|
| |
NYC HealthyTech Connect
|
| With founder/CEOs Josh Gottesman (Embie Clinic), Thiv Paramsothy (Hera Fertility), Gitte Pederson (Genoession), Christine Rohan (Vasowatch), David Hemenway (Founder, Angel Nest), Alex Dundara (Withum). |
| Withum, 1114 Ave Americas, 9th Fl, New York
|
|
Dec 05 (Thu) @ 05:30 PM
| |
FREE |
|
|
|
|
|
|
|
|
| |
| DETAILS |
|
Agenda
5:30 - 6:15pm Cocktail & networking reception
6:15 - 6:30pm Introductions, Alex Dundara, Partner, Withum
6:30 - 6:45pm Investor Introductions, David Hemenway, Founder, Angel Nest
-Sam Schatz, CEO BIOHM, Investor
-Kelly Roman , Co Founder & CEO, Fisher Wallace, Investor
-Aakash Saraiya, MD, investor
-
6:00 - 7:30pm Guest Presenters
- Josh Gottesman , CEO, Embie Clinic
- Thiv Paramsothy, Founder & CEO, Hera Fertility
- Gitte Pederson, Co-Founder & CEO, Genomic Expression
- Christine Rohan, CEO, Vasowatch
7:30 - 8pm Networking
Presenting Companies
Embie Clinic
Embie is enabling 10X more IVF via remote fertility care.
There are only 500 fertility clinics in the entire US but 50,000 OBGYNs. Embie turns any OBGYN office into a satellite fertility clinic, breaking down geographic barriers & drastically improving access to care - while radically improving patient experience.
At a time when everybody is talking about access to IVF, what is not being talked about is the fundamental shortage of the amount of available treatment. And, the deep geographic barriers that effectively make most of the US fertility deserts. Embie's enablement of remote treatment allows for an order of magnitude more IVF independent of geography.
Embie is live with our first two paying US fertility network customers! www.embieclinic.com
Hera Fertility
At Hera Fertility we help men become fathers by treating their infertility comfortably at home instead of in an awkward clinic. Our at-home test & app-based treatment program improve infertility over half the time. https://www.herafertility.co
Genomic Expression
Genomic Expression is revolutionizing cancer treatment by analyzing tumor RNA & identifying the most effective therapies for patients.
Our OneRNA platform is fully validated in breast & ovarian cancer & ready to scale. Supported by industry veterans with $1.7M in seed financing, & $6.5M in grants & $4.5M in lifetime revenue. www.genomicexpression.com
Vasowatch
Vasowatch is an innovative healthcare technology company focused on enhancing maternal health outcomes by providing a non-invasive solution for assessing the risk of postpartum hemorrhage (PPH), a leading cause of maternal mortality. Founded in 2021 & based in Philadelphia, Vasowatch utilizes a wearable device that continuously monitors physiological data during labor & delivery, employing advanced algorithms to predict PPH risk accurately & in real-time. This technology enables healthcare teams to respond promptly to changes in a mother's condition, thereby improving obstetric outcomes & potentially saving lives. By integrating decision support tools into clinical practice, Vasowatch aims to transform maternal care & address health disparities in postpartum management. www.vasowatch.com
|
|
|
|
|
|
|
|
